AnHeart Therapeutics Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Phase 3
Not yet recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Taletrectinib
Drug: Crizotinib
First Posted Date
2024-08-21
Last Posted Date
2024-08-21
Lead Sponsor
AnHeart Therapeutics Inc.
Target Recruit Count
138
Registration Number
NCT06564324

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

First Posted Date
2023-04-18
Last Posted Date
2024-10-18
Lead Sponsor
AnHeart Therapeutics Inc.
Target Recruit Count
9
Registration Number
NCT05814536
Locations
🇨🇳

Beijing Jishuitan Hospital, Beijing, Beijing, China

🇨🇳

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 11 locations

Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene

Phase 2
Recruiting
Conditions
Solid Tumor
Interventions
Drug: AB-106
First Posted Date
2020-11-05
Last Posted Date
2021-06-21
Lead Sponsor
AnHeart Therapeutics Inc.
Target Recruit Count
40
Registration Number
NCT04617054
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, China

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Phase 2
Active, not recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: AB-106
First Posted Date
2020-05-20
Last Posted Date
2023-10-30
Lead Sponsor
AnHeart Therapeutics Inc.
Target Recruit Count
173
Registration Number
NCT04395677
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: DS6051b
First Posted Date
2014-10-31
Last Posted Date
2020-09-22
Lead Sponsor
AnHeart Therapeutics Inc.
Target Recruit Count
46
Registration Number
NCT02279433
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Chao Family Comprehensive Cancer Center of, Orange, California, United States

🇺🇸

Dana Farber Cancer Inst., Boston, Massachusetts, United States

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy